Pharma intelligence for marketing agencies
Gain insight into the pharmaceutical market landscape – we’ll help you communicate complex ideas clearly and develop customer-centric propositions.
With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. As a marketer, you have to engage with multiple audiences across a variety of channels and to communicate complex information simply and persuasively.
We give you the means to identify future innovation and new market opportunities, develop customer-centric propositions, and keep a close eye on competitors. We can also help with branding, multi-channel communication and more.
What we offer
As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our pharma intelligence will help you build a complete picture of the market and get access to past, current and future trends and analysis.
How it helps
You’ll get cutting-edge insights on the size and shape of markets, competitive threats, actionable customer perceptions and industry innovations.
Our accurate, reliable intelligence will help you:
The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.
Key benefits:
A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.
Key benefits:
Unparalleled access to global pharma regulatory and compliance intelligence and expertise.
Key benefits:
Datamonitor Healthcare
By Amanda Micklus 20 Jun 2022
As more regenerative medicine products approach clinical testing and commercialization, seize this opportunity to hear detailed insights and industry best practices from preeminent sector experts. You’ll gain a deep understanding of numerous nurdles unique to bringing durable, curative therapies to patients in need.
Topic cell-and-gene-therapy
18 Jan 2022
The EU will make it mandatory for clinical trial sponsors to prepare layperson summaries of their study results. Industry practices around content presentation, translation and dissemination of these documents will be keenly watched.
Joseph Haas 17 Jan 2022
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
14 Jan 2022
Formed by the FDA in fall 2018 and convened in early 2020 for a public meeting, the Interagency Working Group on Asbestos in Consumer Products maintains that electron microscopy should be a first-line method for detecting asbestos in cosmetic talc and talc-containing products, and that labs should report elongate mineral particles beyond those classically understood as asbestos.
Alaric DeArment 05 Jan 2022
The companies’ third vaccine-development deal shows how COVID cash has also led mRNA-focused companies to beef up their organic pipelines amid talk of a merger wave.
Vibha Ravi 22 Dec 2021
Ocugen’s mutation-agnostic candidate for retinitis pigmentosa and leber congenital amaurosis is set for Phase I trials in the US. In this exclusive audio interview, founder and CEO Shankar Musunuri speaks to Scrip about seeking partners beyond CanSino Biologics for the candidate while stressing Bharat Biotech’s COVID-19 vaccine could hold promise against the Omicron variant.
Andrew McConaghie 29 Nov 2021
While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.
Andrew McConaghie 29 Nov 2021
While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.
01 Nov 2021
In this week's podcast edition of Five Must-Know Things: Lilly goes head-to-head in Alzheimer’s; Roche eyes new opportunities for Lucentis; Novartis doubles down on innovation; BMS seeks growth amid generic threats; and the new head of Boehringer Ingelheim India talks to Scrip.
Malcolm Spicer 31 Oct 2021
While working to improve the quality of VMS products available in the US and to provide information on the products to consumers, the ODS doesn’t have authority to impose change on the industry or in the marketplace.
12 Oct 2021
India leads the ways with the highest number of approved biosimilars.
04 Oct 2021
In this week's podcast edition of Five Must-Know Things: the prospects for Merck’s Acceleron acquisition; the pandemic and biotech capital in-flow; an interview with Menarini’s CEO; upcoming endocrine and metabolic product disorders; and an interview with Novartis Pharma’s president.
Anju Ghangurde 27 Sep 2021
Amgen’s former chief information officer Diana McKenzie highlights the inroads made by technology firms in healthcare and how life science companies can adapt from them while leveraging core capabilities at scale.
26 Sep 2021
In this week's podcast edition of Five Must-Know Things: an interview with the president of Novartis Pharma; Biogen highlights its pipeline; standout comparative data for Enhertu in breast cancer; Sanofi/Regeneron nip at Keytruda’s heels in first-line lung cancer; and a look at the market prospects for wet AMD.
23 Sep 2021
Released July 22, 2021. Contains information like likelihood of approval (LOA) ratings and upcoming catalysts that are current as of April 2021.
28 Jun 2022
27 Jun 2022
27 Jun 2022
27 Jun 2022
27 Jun 2022
Scrip
27 Jun 2022
25 Jun 2022
Scrip
24 Jun 2022
24 Jun 2022
24 Jun 2022
24 Jun 2022
24 Jun 2022
Pink Sheet
24 Jun 2022
23 Jun 2022
23 Jun 2022
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: